Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

A highly fluorescent and readily accessible all-organic photosensitizer model for advancing image-guided cancer PDT

Citation

Garcia-Sampedro, A., Prieto-Castañeda, A., Agarrabeitia, A. R., Bañuelos, J., García-Moreno, I., Villanueva, A., de la Moya, S., Ortiz, M. J., & Acedo, P. (2024). A highly fluorescent and readily accessible all-organic photosensitizer model for advancing image-guided cancer PDT. Journal of Materials Chemistry B, 12(31), 7618-7625. https://doi.org/10.1039/D4TB00385C

Abstract

The potential of using image-guided photodynamic therapy (ig-PDT) for cancer, especially with highly biocompatible fluorescent agents free of heavy atoms, is well recognized. This is due to key advantages related to minimizing adverse side effects associated with standard cancer chemotherapy. However, this theragnostic approach is strongly limited by the lack of synthetically-accessible and easily-modulable chemical scaffolds, enabling the rapid design and construction of advanced agents for clinical ig-PDT. In fact, there are still very few ig-PDT agents clinically approved. Herein we report a readily accessible, easy-tunable and highly fluorescent all-organic small photosensitizer, as a model design for accelerating the development and translation of advanced ig-PDT agents for cancer. This scaffold is based on BODIPY, which assures high fluorescence, accessibility, and ease of performance adaptation by workable chemistry. The optimal PDT performance of this BODIPY dye, tested in highly resistant pancreatic cancer cells, despite its high fluorescent behavior, maintained even after fixation and cancer cell death, is based on its selective accumulation in mitochondria. This induces apoptosis upon illumination, as evidenced by proteomic studies and flow cytometry. All these characteristics make the reported BODIPY-based fluorescent photosensitizer a valuable model for the rapid development of ig-PDT agents for clinical use.

Research Projects

Organizational Units

Journal Issue

Description

Submitted: 23 Feb 2024; Accepted: 01 Jul 2024; First published: 12 Jul 2024. Authors acknowledge grants PID2020-114755GB-C31, -C32 and -C33 funded by Spanish MCIN/AEI/10.13039/501100011033, and grant IT1639-22 funded by Basque Government. A. P.-C. thanks grant FJC2021-046650-I funded by MCIN/AEI/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. P. A. thanks funding from Pancreatic Cancer UK and the Ramon Areces Foundation.

Keywords

Collections